| The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. | |
| | |
MedLine Citation:
|
PMID: 18926729 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Recent in vitro studies showed that celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, protects human osteoarthritic cartilage tissue from degeneration. The objective was to substantiate these beneficial effects in an in vivo (clinical) study with celecoxib treatment of patients with severe knee osteoarthritis (OA) and subsequent evaluation of cartilage tissue ex vivo. METHODS: Patients with knee OA were treated 4 weeks prior to total knee replacement surgery with either celecoxib 200mg b.d., indomethacin 50mg b.d., or received no treatment. During surgery cartilage and synovium were collected and analyzed in detail ex vivo. RESULTS: When compared to non-treated patients, patients treated with celecoxib showed significant beneficial effects on proteoglycan synthesis, -release, and -content, confirming the in vitro data. In the indomethacin group, no significant differences were found compared to the control group. On the contrary, a tendency towards a lower content and lower synthesis rate was found. In the treated groups prostaglandin-E(2) levels were lower than in the control group, indicating COX-2 inhibition. Ex vivo release of interleukin-1 beta (IL-1 beta) and tumour necrosis factor-alpha by synovial tissue was decreased by treatment with celecoxib, whereas in the indomethacin group only IL-1 beta release was decreased. CONCLUSION: Using this novel approach we were able to demonstrate an in vivo generated chondrobeneficial effect of celecoxib in patients with end stage knee OA. |
| | |
Authors:
|
T N de Boer; A M Huisman; A A Polak; A G Niehoff; A C van Rinsum; D Saris; J W J Bijlsma; F J P G Lafeber; S C Mastbergen |
Related Documents
:
|
3654709 - Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-fe... 12892189 - Secondary resurfacing of the patella for persistent anterior knee pain after primary kn... 576779 - Intensive physical therapy after meniscectomy. 19653049 - Autologous chondrocyte implantation for joint preservation in patients with early osteo... 17043539 - Can a nurse-directed intervention reduce the exposure of patients with knee osteoarthri... 16703819 - An acute care episode of a patient following bilateral total knee arthroplasty. 21697199 - Postural asymmetries in transfemoral amputees. 15021279 - Buprenorphine-soaked absorbable gelatin sponge: an alternative method for postlaminecto... 18690349 - The efficacy of antithrombin administration in the acute phase of burn injury. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2008-10-15 |
Journal Detail:
|
Title: Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society Volume: 17 ISSN: 1522-9653 ISO Abbreviation: Osteoarthr. Cartil. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-03-13 Completed Date: 2010-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9305697 Medline TA: Osteoarthritis Cartilage Country: England |
Other Details:
|
Languages: eng Pagination: 482-8 Citation Subset: IM |
Affiliation:
|
Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. t.n.deboer-4@umcutrecht.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Arthroplasty, Replacement, Knee Cartilage, Articular / drug effects*, metabolism, pathology Cyclooxygenase 2 Inhibitors / therapeutic use* Dinoprostone / biosynthesis Female Humans Indomethacin / therapeutic use Interleukin-1beta / metabolism Male Matrix Metalloproteinases / metabolism Middle Aged Nitric Oxide / biosynthesis Osteoarthritis, Knee / drug therapy*, metabolism, pathology, surgery Proteoglycans / metabolism Pyrazoles / therapeutic use Sulfonamides / therapeutic use Synovial Membrane / drug effects, metabolism Tumor Necrosis Factor-alpha / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Interleukin-1beta; 0/Proteoglycans; 0/Pyrazoles; 0/Sulfonamides; 0/Tumor Necrosis Factor-alpha; 10102-43-9/Nitric Oxide; 169590-42-5/celecoxib; 363-24-6/Dinoprostone; 53-86-1/Indomethacin; EC 3.4.24.-/Matrix Metalloproteinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expectations prior to epilepsy surgery: an exploratory comparison of men and women.
Next Document: Melanoma with cartilaginous differentiation originating within the mucosa of the nasal cavity.